1,394 reports of this reaction
2.8% of all MOMETASONE reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for MOMETASONE, manufactured by Amneal Pharmaceuticals LLC. There are 1,394 FDA adverse event reports linking MOMETASONE to HEADACHE. This represents approximately 2.8% of all 48,940 adverse event reports for this drug.
Patients taking MOMETASONE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for MOMETASONE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for MOMETASONE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,394 FDA reports for MOMETASONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.8% of all adverse event reports for MOMETASONE, making it a notable side effect.
If you experience headache while taking MOMETASONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.